Carbapenems in serious infections : A risk-benefit assessmentNORRBY, S. R.Drug safety. 2000, Vol 22, Num 3, pp 191-194, issn 0114-5916Article

Effect of cilastatin on cyclosporine-induced acute nephrotoxicity in kidney transplant recipientsCARMELLINI, M; FROSINI, F; FILIPPONI, F et al.Transplantation. 1997, Vol 64, Num 1, pp 164-166, issn 0041-1337Article

Cross-reactivity and tolerability of imipenem in patients with delayed-type, cell-mediated hypersensitivity to β-lactamsSCHIAVINO, D; NUCERA, E; LOMBARDO, C et al.Allergy (Copenhagen). 2009, Vol 64, Num 11, pp 1644-1648, issn 0105-4538, 5 p.Article

Separation, identification, and quantification of N-acetyl cilastatin in human urineHSIEH, J. Y.-K; MAGLIETTO, B. K; BAYNE, W. F et al.Journal of liquid chromatography. 1985, Vol 8, Num 3, pp 513-520, issn 0148-3919Article

Use of imipenem-cilastatin in pediatricsOVERTURF, G. D.The Pediatric infectious disease journal. 1989, Vol 8, Num 11, pp 792-794, issn 0891-3668, 3 p.Article

Cilastatin does not alter superoxide dismutase activityPROCTOR, R. A; TEXTOR, J. A.Antimicrobial agents and chemotherapy. 1985, Vol 28, Num 5, pp 691-692, issn 0066-4804Article

Newer carbapenems for urinary tract infectionsMATSUMOTO, Tetsuro; MURATANI, Tetsuro.International journal of antimicrobial agents. 2004, Vol 24, pp S35-S38, issn 0924-8579, SUP1Conference Paper

Industrial production of chiral intermediate of cilastatin by nitrile hydratase and amidase catalyzed one-pot, two-step biotransformationZHENG, Ren-Chao; YANG, Zhong-Yi; LI, Cong-Cheng et al.Journal of molecular catalysis. B, Enzymatic. 2014, Vol 102, pp 161-166, issn 1381-1177, 6 p.Article

Elevated plasma cysteinylglycine levels caused by cilastatin- associated antibiotic treatmentBADIOU, Stéphanie; BELLET, Hélène; LEHMANN, Sylvain et al.Clinical chemistry and laboratory medicine. 2005, Vol 43, Num 3, pp 332-334, issn 1434-6621, 3 p.Article

Adverse Events Associated With Meropenem Versus Imipenem/Cilastatin Therapy in a Large Retrospective Cohort of Hospitalized InfantsHORNIK, Christoph P; HERRING, Amy H; BENJAMIN, Daniel K et al.The Pediatric infectious disease journal. 2013, Vol 32, Num 7, pp 748-753, issn 0891-3668, 6 p.Article

Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergyPRESCOTT, William A; KUSMIERSKI, Kristen A.Pharmacotherapy. 2007, Vol 27, Num 1, pp 137-142, issn 0277-0008, 6 p.Article

Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumoniaJOSHI, Manjari; METZLER, Michael; MCCARTHY, Mary et al.Respiratory medicine. 2006, Vol 100, Num 9, pp 1554-1565, issn 0954-6111, 12 p.Article

Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patientsKELLER, E; FECHT, H; BÖHLER, J et al.Nephrology, dialysis, transplantation (Print). 1989, Vol 4, Num 7, pp 640-645, issn 0931-0509, 6 p.Article

Imipenem/cilastatin treatment of bacterial meningitis in childrenWONG, V. K; WRIGHT, H. T; ROSS, L. A et al.The Pediatric infectious disease journal. 1991, Vol 10, Num 2, pp 122-125, issn 0891-3668Article

Chimiothérapie anti-infectieuse = Antiinfectious chemotherapyCLARA, F.Médecine et hygiène. 1986, Vol 44, Num 1638, pp 15-22, issn 0025-6749Article

Imipenem-cilastatin in pediatric patients: an overview of safety and efficacy in studies conducted in the United StatesAHONKHAI, V. I; CYHAN, G. M; WILSON, S. E et al.The Pediatric infectious disease journal. 1989, Vol 8, Num 11, pp 740-744, issn 0891-3668, 5 p.Article

Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections : Results of a prospective, randomized, multicentre trialBASOLI, A; MELI, E. Z; MAZZOCCHI, P et al.Scandinavian journal of infectious diseases. 1997, Vol 29, Num 5, pp 503-508, issn 0036-5548Article

Empiric carbapenem monotherapy in pediatric bone marrow transplant recipientsNELSON, Wendelin K; RAYBACK, Priscilla A; QUINONES, Ralph et al.The Annals of pharmacotherapy. 2002, Vol 36, Num 9, pp 1360-1365, issn 1060-0280, 6 p.Article

Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulationLEE, Lois S; KINZIG-SCHIPPERS, Martina; NAFZIGER, Anne N et al.Diagnostic microbiology and infectious disease. 2010, Vol 68, Num 3, pp 251-258, issn 0732-8893, 8 p.Article

Imipenem-cilastatin induced pure white cell aplasiaKMAMBOKIS, Georgios; VASSOU, Amalia; BOURANTAS, Konstantinos et al.Scandinavian journal of infectious diseases. 2005, Vol 37, Num 8, pp 619-620, issn 0036-5548, 2 p.Article

In vitro effects of meropenem and imipenem/cilastatin on some functions of human natural effector cellsCORNACCHIONE, P; SCARINGI, L; CAPODICASA, E et al.Chemotherapy (Basel). 2000, Vol 46, Num 2, pp 135-142, issn 0009-3157Article

Empiric therapy of sepsis in the surgical intensive care unit with broad-spectrum antibiotics for 72 hours does not lead to the emergence of resistant bacteriaNAMIAS, N; HARVILL, S; BALL, S et al.The Journal of trauma. 1998, Vol 45, Num 5, pp 887-891, issn 0022-5282Conference Paper

Assessment of an Alternative Meropenem Dosing Strategy Compared with Imipenem-Cilastatin or Traditional Meropenem Dosing After Cefepime Failure or Intolerance in Adults with Neutropenic FeverARNOLD, Heather M; MCKINNON, Peggy S; AUGUSTIN, Kristan M et al.Pharmacotherapy. 2009, Vol 29, Num 8, pp 914-923, issn 0277-0008, 10 p.Article

Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically IIIHASHIMOTO, S; HONDA, M; YAMAGUCHI, M et al.ASAIO journal (1992). 1997, Vol 43, Num 1, pp 84-88, issn 1058-2916Article

Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections : Report from a Swedish Study GroupBRISMAR, B; AKERLUND, J.-E; ANGERAS, M et al.Scandinavian journal of infectious diseases. 1996, Vol 28, Num 5, pp 507-512, issn 0036-5548Article